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ABSTRACT
Rationale The response characteristics of the 6 minute
walk test (6MWT) in studies of idiopathic pulmonary
fibrosis (IPF) are only poorly understood, and the change
in walk distance that constitutes the minimum important
difference (MID) over time is unknown.
Objectives To examine changes over time in distance
walked (ie, 6MWD) during the 6MWT and to estimate
the change in distance that constitutes the MID in
patients with IPF.
Methods Data from a recently completed trial that
included subjects with IPF who completed the 6MWT,
Saint George’s Respiratory Questionnaire (SGRQ) and
forced vital capacity (FVC) at 6 and 12 months were used
to examine longitudinal changes in 6MWD. Both anchor-
and distribution-based approaches as well as linear
regression analyses were used to determine the MID for
6MWD. The SGRQ Total score and FVC were used as
clinical anchors.
Main results Among 123 subjects alive and able to
complete the 6MWT at both follow-up time points,
6MWD did not change significantly over time (378.1 m
at baseline vs 376.8 m at 6 months vs 361.3 m at
12 months, p¼0.5). The point estimate for the 6MWD
MID was 28 m with a range of 10.8e58.5 m.
Conclusion In a group of patients with IPF with
moderate physiological impairment, for those alive and
able to complete a 6MWT, 6MWD does not change over
12 months. At the population level, the MID for 6MWD
appears to be w28 m. Further investigation using other
anchors and derivation methods is required to refine
estimates of the MID for 6MWD in this patient population.
INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a progressive,
fatal fibrosing interstitial lung disease that impairs
functional status and quality of life. Although
recent advances in our understanding of the
underlying pathogenesis of IPF have led to the
investigation of numerous profibrotic pathways,1
no medical treatment has been shown to improve
respiratory symptoms or functional status, or to
prolong survival.
The 6 minute walk test (6MWT) is a simple and
easily performed assessment of a subject’s
submaximal functional capacity. It measures the
distance a patient can walk on a flat surface over
a period of 6 min and is used to measure the
response to medical interventions in patients with
moderate to severe cardiac or pulmonary disease.2
Its reproducibility (with a coefficient of variation of
w8%) appears to be better than the 1 s forced
expiratory volume in patients with chronic
obstructive pulmonary disease (COPD),3e6 and it
has less short-term variability than questionnaire
indices of functional status (22e33%).7
For IPF, the 6 minute walk distance (6MWD)
appears highly reproducible (testeretest reliability
0.98) over short time intervals (eg, 1e2 weeks), and
is highly correlated (r ¼ 0.78) withmaximal oxygen
uptake derived from a maximal cardiopulmonary
exercise test.8 In two relatively small studies, inves-
tigators have examined changes in distance walked
during the 6MWT over longer time periods in
patients with confidently defined IPF. Tomioka and
colleagues9 found that 6MWD declined to a non-
significant degree (37.3 6 120.9 m, p ¼ 0.2) from
baseline among 32 subjects with IPF who completed
a 6MWTafter a median 14 months of follow-up. In
a recently completed placebo-controlled study
investigating the efficacy of etanercept in the treat-
ment of IPF, the 6MWT was used as a secondary
endpoint. In terms of 6MWD, there was no statis-
tically significant difference between the two treat-
ment arms, and subjects in the placebo arm (n ¼ 41)
experienced a mean decline of 14.7 (6112.5) m
(p ¼ 0.5) at week 48, with changes of 2.2
(665.80), 2.1 (671.7) and 22.3 (6106.8) m at
weeks 12, 24 and 36, respectively.10
What is not known about the 6MWT in patients
with IPF is what distance constitutes the minimum
important difference (MID)dthe smallest change
in distance that patients can perceive as different
from the previous test and that would mandate, in
the absence of troublesome side effects and exces-
sive costs, a change in management.11 Several
methods can be used to determine the MID for an
outcome measure, but there is much controversy
over which ones are best.12 A common approach is
to use multiple methods to derive MID estimates.
Onedthe anchor-basedmethoddcalls for a different
but related clinical variable to be a so-called
anchor; the mean change in the outcome (eg,
6MWD) calculated for subjects who change
“minimally” according to that anchor is the MID
estimate. There are no restrictions on what variables
can serve as anchors; however, any anchor must be
clinically relevant and cut-off values for defining
minimal change should be sensible. Distribution-
based methods, including the effect size, stand-
ardised response mean and standard error of
measurement, use statistical calculations based
solely on study sample data for the outcome vari-
able to derive the MID.
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The goals of this study were to determine the changes in
6MWD over time in a large, well-defined sample of subjects with
IPF with moderate physiological impairment and to use multiple
approaches to determine the MID for 6MWD in this population.
METHODS
Patient population
Data from the international, prospective, double-blinded, rand-
omised, placebo-controlled, parallel group study investigating
the use of bosentan in the treatment of patients with IPF
(BUILD-1) were analysed.13 Its study design, inclusion and
exclusion criteria, and primary results have been previously
published.13 Briefly, patients were enrolled in BUILD-1 if their
IPF diagnosis met American Thoracic Society (ATS)/European
Respiratory Society (ERS) consensus guidelines,14 if they were
diagnosed with IPF between 3 and 36 months prior to enrolment,
and if a screening 6MWD was between 150 and 499 m. Patients
were excluded if they had a forced vital capacity (FVC) of <50%
or >90% predicted,15 a diffusing capacity for carbon monoxide
(DLCO) corrected for haemoglobin level <30% predicted,16
a resting arterial oxygen pressure (PaO2) <55 mm Hg (sea level)
or 50 mm Hg (>1400 m), echocardiographic evidence of severe
pulmonary hypertension (systolic pulmonary pressure>50 mm
Hg or tricuspid regurgitation velocity >3.2 m/s) or severe
congestive heart failure. The study was approved by the appro-
priate independent ethics committees or institutional review
boards and conducted in accordance with the principles of the
Declaration of Helsinki, local laws and guidelines for good clinical
practice. All patients provided written, informed consent. Our
study sample was comprised of subjects with baseline, 6 and
12 month 6MWD data.
Study protocol
The 6MWD was measured without supplemental oxygen using
a modified 6MWT protocol, conducted in accordance with ATS
guidelines,2 but terminated prematurely if SpO2 fell below 80%
(pulse oximeter; Nellcor N-595; Pleasanton, California, USA).
Technicians conducting the 6MWT were blinded to all ques-
tionnaire data.
Assessment tools
The Saint George’s Respiratory Questionnaire (SGRQ) is a self-
administered, obstructive lung disease-specific questionnaire
with 50 items comprising three domains (Symptoms, Activity
and Impact) and a Total score. Domain and Total scores range
from 0 to 100, with higher scores corresponding to worse health-
related quality of life.
Statistical analysis
Descriptive statistics were used for baseline, 6 month and
12 month data. Change over time in 6MWD was examined by
using longitudinal data analytic methods. We used SAS PROC
MIXED (SAS Institute, Cary, North Carolina, USA) to model
mean 6MWD at each study time point (baseline, 6 and
12 months) while handling the within-subject correlation of
repeated measures of 6MWD. Thus, the model yielded least
squared means estimates for 6MWD at each of the three time
points, and the null hypothesis of equality among the three mean
values for a given variable was tested. Even with mild deviations
from normality and particularly for sample sizes >100dthe data
from this sample of 123 subjects were mildly skeweddPROC
MIXED will yield robust estimates.
Next, we stratified subjects according to anchor score changes
(SGRQ Total score and FVC) over the two time intervalsdfrom
baseline to 6 months as well as 6e12 months. The SGRQ Total
was chosen as an anchor because it captures patients’ perceptions
about their own health status; thus it assesses certain effects of
IPF on patient well-being. In a previous study, we determined the
MID for the SGRQ Total to be 7 points, with a range of 5e10
points. Thus, for this analysis, we categorised subjects as
“unchanged” if the difference in SGRQ Total was within 5 points
(exclusive) of the value at the previous time point, as “changed
minimally” if the difference in SGRQ Total was 5e10 points
(exclusive) different from the previous time point, and as
“changedmore thanminimally” if the difference was$10 points.
For each time interval, the mean change in 6MWD was calcu-
lated for subjects stratified according to categorical changes (ie,
unchanged, changed minimally or changed more than mini-
mally) in SGRQ Total score. To show the ability of SGRQ Total
to discriminate between subjects whose 6MWD changed over
time, we used repeated measures analysis of variance (ANOVA)
to compare linear contrasts in mean changes in 6MWD across
categories of change in SGRQ Total score. We used this same
Table 1 Baseline characteristics of the entire study
sample
All subjects (N[154)
Age 65.1 (8.74)
M:F 73:27
Height (cm) 170.0 (8.4)
Weight (kg) 84.7 (15.87)
FVC (litres) 2.6 (0.71)
FVC% 67.8 (11.84)
DLCO 4.1 (1.18)
DLCO% 41.8 (9.48)
Baseline 6MWD 372.9 (82.63)
150e249 m (n¼15) 200.9 (29.3)
250e349 m (n¼37) 309.5 (28.7)
350e450 m (n¼102) 421.7 (40.4)
Data are presented as mean (SD) or percentages for gender.
DLCO, diffusing capacity for carbon monoxide; F, female; FVC, forced vital
capacity; M, male, 6MWD, 6 minute walk distance.
Figure 1 Mean 6 minute walk distance (6MWD) in metres
at baseline, 6 months and 12 months for the subjects alive
and able to complete the 6 minute walk test (6MWT) at all
three time points. Dots indicate the mean 6MWD in metres.
Whiskers depict 95% CIs. Mixed model p¼0.5 for difference
between 6MWD at three time points.
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approach for the FVC anchor: first, stratifying the sample on
change in FVC, then calculating mean changes in 6MWD for
categories of change in FVC, and finally using repeated measures
ANOVA to compare changes in 6MWD across FVC categories.
For FVC, we categorised subjects as “unchanged” if the difference
in the raw FVC was within 7% (inclusive) of the value at the
previous time point, as “changed minimally” if the difference in
the raw FVC value was between 7% and 12% (exclusive) of the
value at the previous time point, and as “changed more than
minimally” if the difference was $12%. We considered a 7e12%
change in raw FVC as a minimally important change because this
range covers 7% (a so-called marginal change that has been
shown to carry prognostic significance in IPF17 18) as well as 10%
(a commonly used endpoint in trials and in clinical practice14).
To estimate the MID for 6MWD, we calculated weighted
averages for 6MWD for subjects with minimal change in the
SGRQ Total (5e10 points) or FVC anchor (7e12% from the
baseline raw value). We next used the within-patient anchor-
based method19 to derive another MID estimate for 6MWD. For
this method, linear regression is used to examine the relationship
between changes in 6MWD (dependent variable) and changes in
the anchordSGRQ Total score or FVC% (independent variables).
Lastly, we used distribution-based methods to generate MID
estimates. The effect size (referred to as ES and calculated as the
change in 6MWD divided by the SD of the baseline 6MWD) is
one such method.20 For ES, values of 0.2 are considered small
effects, 0.5 medium effects, and 0.8 large effects. Although there
is no consensus about how or even whether12 ES should be used
in the estimation of MIDs, some investigators consider 0.5 to
correspond to the MID.21 22 Thus, we derived the change in
6MWD that would correspond to an ES of 0.5 and used that as an
MID estimate. All analyses were performed with SAS version
9.1.3 (SAS Institute), and p values <0.05 were considered
statistically significant.
RESULTS
Themean age of the samplewas 65 years, and most subjects were
men (table 1). Among all subjects able to complete a 6MWT at
baseline and at both 6 and 12 month follow-up (n¼123), there
was no statistical difference in mean 6MWD between any time
point (figure 1). Further, table 2 shows that baseline walk distance
appeared not to influence subsequent measures of 6MWD.
Statistically significant relationships were observed between
change in 6MWD and change in SGRQ Total score or FVC (table 3).
Table 4 gives MID estimates from distribution- and anchor-based
approaches. The distribution-based approach (ES¼0.5) yielded
a higher estimate than the anchor-based approaches. The mean
of all MID point estimates yielded a value of 28 m.
DISCUSSION
For patients with IPF, the 6MWTappears to be a valid reflection
of global functional capacity8; it is frequently used clinically to
assess changes in IPF disease status over time but with few data
to support this practice. More importantly, the 6MWTdeither
the 6MWT itself, variations thereof or data collected during the
6MWT (eg, measures of oxygenation)dhas been used as an
outcome measure in trials enrolling subjects with IPF.23e25
However, there are large knowledge gaps regarding certain
important aspects of this test in IPF.
In this study, for a select group of well-defined subjects with
IPF who were able to walk no less than 150 m and no more than
499 m during a baseline 6MWT, and who performed follow-up
testing, we found no significant change from baseline in 6MWD
at 6 or 12 months. These data are supported by studies from
Tomioka and Raghu who also found no significant change over
time frames ranging from about 12 to 14 months.9 10
Our study estimates the MID for 6MWD in patients with IPF,
which we found to be in the range of 28 m. To our knowledge,
only two other groups of investigators have assessed the MID for
the 6MWD in patients with IPF. In a study published only in
abstract form, Mathai and colleagues divided into two subgroups
20 patients with IPF who were participating in a 1 day support
group. Each patient performed a 6MWT, and then each subgroup
of 10 patients spent the day together at a support group meeting
(details not provided). At the end of the day, each patient was
asked to rate his ability to walk relative to the other members in
his subgroup. These investigators found that 6MWD needed to
differ by a mean 17.96103.6 m for patients to stop rating
themselves as “the same” as other members in their group.
Redelmeier and colleagues developed this method, and used it to
show that the MID for 6MWD in patients with COPD is 54 m
Table 2 Longitudinal change in 6MWD for the subgroup alive and able
to complete the 6MWT
Baseline 6 months 12 months p Value
Baseline 6MWD
150e249 m (n¼11) 198.3 (32) 211.5 (127.5) 172.5 (118.8) 0.7
250e349 m (n¼28) 311.3 (28.5) 279.4 (106) 262.9 (110.2) 0.13
350e499 m (n¼84) 424.5 (39.6) 430.9 (77) 419.5 (97.5) 0.6
Data are presented as mean (SD). p Value from repeated measures ANOVA that compared
within-group 6MWD between time points.
6MWD, 6 minute walk distance; 6MWT, 6 minute walk test.
Table 3 Mean 6MWD for the subgroup alive and able to complete the 6MWT at all three time points stratified by the SGRQ and FVC anchors
SGRQ total score
Worsened ‡10 Worsened 5e10 Within 4.9 points Improved 5e10 Improved ‡10
Baseline to 6 months n¼16
39.0 (128.2)
n¼19
6.6 (77.3)
n¼36
8.0 (58.6)
n¼16
15.8 (47.1)
n¼34
2.9 (76.7)
6e12 months n¼17
84.6 (111.2)
n¼20
20.2 (49.0)
n¼48
10.4 (67.4)
n¼14
25.9 (58.4)
n¼24
5.6 (57.9)
FVC
Declined $12% Declined 7e12% No change Improved 7e12% Improved $12%
Baseline to 6 months n¼17
56.1 (111.9)
n¼24
20.6 (105.4)
n¼65
11.7 (49.6)
n¼9
8.8 (35.6)
n¼8
56.8 (43.1)
6e12 months n¼18
33.8 (74.1)
n¼23
51.6 (99.8)
n¼71
2.4 (65.2)
n¼9
11.2 (56.9)
n¼2
9.5 (67.2)
Data are presented as mean (SD). Tests of significance for linear contrast in group effect yielded p¼0.05 for baselinee6 months and p¼0.0001 for 6e12 months for SGRQ Total and p¼0.0003 for
baselinee6 months and p¼0.2 for 6e12 months for FVC.
FVC, forced vital capacity; 6MWD, 6 minute walk distance; 6MWT, 6 minute walk time; SGRQ, Saint George’s Respiratory Questionnaire.
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(95% CI 37 to 71 m); that is, the mean difference in 6MWD
between subjects who rated themselves as being able to walk
either “a little bit better” or “a little bit worse”, compared with
those who rated themselves as being able to walk “about the
same” as other patients, was 54 m. In that study, patients who
rated themselves as “a little worse” on average walked 80 m less
than other patients in their group, whereas subjects who rated
themselves as “a little better” walked only 30 m more than other
patients in their groupdyielding a weighted average of 54 m
among subjects who rated themselves as minimally (or “a
little.”) different from other patients.
Another method commonly used to determine the MID for an
outcome measure involves asking subjects to provide a so-called
transition assessment at the time of follow-up testing. For
example, at 6 months, subjects (blinded to baseline and follow-
up data) might be asked to report whether they perceived their
6MWD to be “the same as”, “a little bit less”, “a lot less”, “a little
bit greater” or “a lot greater” than their baseline walk. The mean
6MWD for subjects reporting a minimal change in perceived
6MWD (ie, “a little bit less” or “a little bit greater”) would be the
estimate of the MID. Singh and co-investigators used this
method to estimate the MID for the incremental shuttle walk
test to be 47.5 m in patients with COPD.26 In the only study of
the 6MWDMID in IPF published in manuscript format, Holland
and her colleagues used global change ratings, receiver operating
characteristic (ROC) curves and a distribution-based approach to
derive their estimate.27 Among 24 subjects with IPF who
completed a 6MWT before and after an 8 week exercise
programme, the MID was found to be between 29 and 34 m.
No transition assessmentwas used in the BUILD-1 trial, butwe
employed a related (and perhaps the most common) method of
determining the MIDdan anchor-based method. Although any
variable can be an anchor, each should meet three criteria: (1) it
should be related to the outcome variable; (2) it must possess face
validity; and (3) it must be able to be divided into at least three
categories: no change, minimal and other.12 As one anchor, we
selected the SGRQ Total for several reasons: (1) it is a patient-
oriented or patient-assessed outcome measure and, as such, it
asks specifically about patients’ perceptions28da notion viewed
by many investigators as paramount to deriving the MID for an
outcome variable12; (2) IPF impairsdand patients valuedthe
quality of their lives, so the SGRQ and other health status
questionnaires provide meaningful data in this population29 30;
and (3) we have shown previously that a 7-point change in SGRQ
Total score is its MID among patients with IPF.31 As the second
anchor we chose the FVC because it is perhaps the most widely
used physiological measurement to assess IPF severity, and cut-
off values for its clinical and prognostic meaningfulness have
been established in a number of studies.32e36 We elected to use
FVC rather than DLCO because of the greater intrinsic variability
in DLCO measures as well as our inability to define confidently
the clinically significant range for its minimum change.
There are a number of limitations to this study. As is often the
case, the distribution-based method yielded higher estimates for
the MID than the anchor-based methods.37 The selected popu-
lation included only patients with IPF who could walk >150 m
but <499 m during a 6MWTat baselinedand the overwhelming
majority could walk at least 350 m. Furthermore, data from
subjects who died, or who were unable to complete the 6MWT
for other reasons, were not included in our analyses; this could
introduce bias. Thus, inferences drawn here may not be appli-
cable to extremely debilitated patients with IPF in the latter
stages of the disease or to more fit patients with IPF in the earlier
stages of disease. However, the results of this study may have
important implications for both IPF investigators who plan to
power future IPF studies for change in 6MWD as well as clini-
cians who prognosticate future changes in functional status.
While the pattern of decline in 6MWD over time is unclear, if
a linear decline were assumed, one might expect a 30 m decline in
6MWD to occur, on average, at 31 months of follow-up (data not
shown). It has been recommended that multiple anchors (in
multiple studies) be used to generate a range for the MID for any
outcome variable.12 Although this is but one study, we derived
the MID for 6MWD by using two clinically meaningful anchors
as well as by employing distribution-based methods. Further-
more, our estimate is nearly identical to the estimate from the
only other published study to examine the 6MWD MID in IPF.
Finally, it must be recognised that the MID estimate here is to be
used at the population level; that is, the mean change in 6MWD
that is considered clinically important in a population is “often
much less” than the change in 6MWD that would allow a prac-
titioner to be confident that a change within an individual
patient is outside of the inter-test variability.37
In conclusion, data from this study provide the first system-
atic examination of 12 month longitudinal changes in 6MWD as
a prospectively acquired, primary outcome variable in a well-
defined subset of patients with IPF, as well as an estimate of the
MID for 6MWD in patients with this disease. It appears as
though the MID for 6MWD is smaller for IPF than for COPD,
but future confirmatory studies should be performed to estimate
the MID for 6MWD in IPF.
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Table 4 MID estimates for 6MWD
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20.7
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D6MWD¼22.9 (6.9 to 39.9)
D6MWD¼1.9 +(4.4)(DSGRQt)
Corresponding to 7 unit change in SGRQt,
D6MWD¼32.7 (25 to 41.1)
35.4
Grand mean¼28, thus MID¼28 m.
The 95% CIs around the MID estimates from the regression equations are sample size dependent. The point estimates should be viewed as the best estimates of the MID.
*Weighted mean of subjects whose raw FVC changed by 7e12% over the indicated time interval.
ES, effect size; FVC, forced vital capacity; MID, minimum important difference; 6MWD, 6 minute walk distance; SGRQt, Saint George’s Respiratory Questionnaire SGRQ Total.
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